[HTML][HTML] Striatal dopamine neurotransmission: regulation of release and uptake
Dopamine (DA) transmission is governed by processes that regulate release from axonal
boutons in the forebrain and the somatodendritic compartment in midbrain, and by …
boutons in the forebrain and the somatodendritic compartment in midbrain, and by …
[HTML][HTML] Cannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in Parkinson's disease
F Patricio, AA Morales-Andrade… - Frontiers in …, 2020 - frontiersin.org
The phytocannabinoids of Cannabis sativa L. have, since ancient times, been proposed as a
pharmacological alternative for treating various central nervous system (CNS) disorders …
pharmacological alternative for treating various central nervous system (CNS) disorders …
Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1–A2A receptor heteromers
The functional role of heteromers of G-protein-coupled receptors is a matter of debate. In the
present study, we demonstrate that heteromerization of adenosine A 1 receptors (A 1 Rs) …
present study, we demonstrate that heteromerization of adenosine A 1 receptors (A 1 Rs) …
An update on the mechanisms of the psychostimulant effects of caffeine
S Ferré - Journal of neurochemistry, 2008 - Wiley Online Library
There has been a long debate about the predominant involvement of the different adenosine
receptor subtypes and the preferential role of pre‐versus post‐synaptic mechanisms in the …
receptor subtypes and the preferential role of pre‐versus post‐synaptic mechanisms in the …
Adenosine A2A receptors and basal ganglia physiology
Adenosine A2A receptors are highly enriched in the basal ganglia system. They are
predominantly expressed in enkephalin-expressing GABAergic striatopallidal neurons and …
predominantly expressed in enkephalin-expressing GABAergic striatopallidal neurons and …
Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002 …
Objective Based on new understanding of nondopaminergic pathways involved in
Parkinson's disease (PD) pathophysiology, a selective adenosine A2A receptor antagonist …
Parkinson's disease (PD) pathophysiology, a selective adenosine A2A receptor antagonist …
Purinergic signalling in brain ischemia
Ischemia is a multifactorial pathology characterized by different events evolving in the time.
After ischemia a primary damage due to the early massive increase of extracellular …
After ischemia a primary damage due to the early massive increase of extracellular …
Systematic review on Parkinson's disease medications, emphasizing on three recently approved drugs to control Parkinson's symptoms
P Sivanandy, TC Leey, TC Xiang, TC Ling… - International journal of …, 2021 - mdpi.com
Parkinson's Disease (PD) is a disease that involves neurodegeneration and is characterised
by the motor symptoms which include muscle rigidity, tremor, and bradykinesia. Other non …
by the motor symptoms which include muscle rigidity, tremor, and bradykinesia. Other non …
The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease
A Mori, JF Chen, S Uchida, C Durlach, SM King… - Molecules, 2022 - mdpi.com
The adenosine A2A receptor subtype is recognized as a non-dopaminergic
pharmacological target for the treatment of neurodegenerative disorders, notably …
pharmacological target for the treatment of neurodegenerative disorders, notably …
Ecto-5′-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions
Adenosine is a neuromodulator acting through inhibitory A1 receptors (A1Rs) and facilitatory
A2ARs, which have similar affinities for adenosine. It has been shown that the activity of …
A2ARs, which have similar affinities for adenosine. It has been shown that the activity of …